Nash Pharmaceuticals, a wholly-owned subsidiary of
Breathtec Biomedical Inc. (
CSE: BTH,
OTCQB: BTHCD,
Forum), announced on Monday that its lead compound for the treatment of ulcerative colitis (UC), performed as good as, and in some measurements, better than, the current global standard of care treatment for inflammatory bowel disease (IBD). This means that a new potential treatment for Crohn’s disease could lead to an orphan drug designation, which could help expedite its availability to patients.
For more information,
click here.
The Company recently made news when it stated that that one of its lead compounds for chronic kidney disease (“CKD”) NP-135 showed positive results in a recently completed study investigating its therapeutic effects in a unilateral ureteral obstruction mouse model of kidney fibrosis.
FULL DISCLOSURE: Breathtec Biomedical Inc. is a paid client of Stockhouse Publishing.